Back to Dashboard
25

NEOG

đŸ„ Healthcare

Neogen Corporation

Conservative #1199Aggressive #1238High RiskMixed 55F↑ 15pt
$11.14-1.37%
Day High$11.42
Day Low$11.13
Volume0.4M
Mkt Cap$2.4B
52W Low $452W High $11
Market Cap
$2.5B
P/E Ratio
N/A
Rev Growth
-3.2%
Sector avg: 161.5%
Earnings Growth
-11491.6%
Profit Margin
-68.5%
Sector avg: -3292.7%
Debt/Equity
0.38

Why This Score

NEOG scores 24.6 on the Conservative profile, blending a fundamental score (80% weight, emphasizing quality and stability (84% of fundamental weight)) with a machine-learning signal (20% weight) trained on 82 features across 30 years of data.

Risk Factors
  • Above-average volatility (21.4%) may not suit conservative risk tolerance.

Minor adjustments (-0.9 points) applied. NEOG's rank of #1199 primarily reflects its factor profile relative to the conservative weight vector.

Score Breakdown

Overall Score24.6
Fundamental Score28.0
ML Score7.0

Score by Horizon

3 Month
38.1
6 Month
42.6
Primary
1 Year
44.8

Quality Assessment

D
Earnings Grade
Weak fundamentals or significant quality concerns

Position Sizing

Suggested Allocation
3.7%
Confidence
high

Score Composition Waterfall

How each component affects the final score
Backtested Scoring Levers (IC-calibrated from 30y ElasticNet)
Weinstein (12.1%)
100
Advancing
Sentiment (2.5%)
42
Neutral
Analyst (6.4%)
50
Neutral
Tradability (post-hoc)
93
Grade A
Base
23.9
SHAP
+1.2
Factors
+0.4
Divergence
-0.9
Final
24.6
Positive adjustment
Negative adjustment
Base blend
Final score

Signal SegmentsComputed from ML features

Fundamental (Valuation, Quality, Growth)39.0
Technical (Momentum, Weinstein, Volatility)65.0
External (Sentiment, Analyst, Macro)61.0
Scores below 50 indicate weakness in that segment relative to the universe.

Data Quality

Score
Features
Confidence
Feature Coverage89%

Growth Estimates

Short-term
-6.7% to -2.0%
Medium-term
-9.4% to -2.4%
Long-term
-12.1% to -2.9%

ML Model Core Features100 trained inputs → ML Score: 7

These features are direct inputs to the machine learning model. The model was trained on these signals alongside 100 features (including 12 momentum/technical indicators) to produce the ML percentile score.

Analyst Intelligence
Consensus Score50.0/100
Target Upside+0.0%
Coverage0 analysts
Market Sentiment
Sentiment Score42.1/100
News Volume0 articles
Technical Stage
Weinstein Stage2 — Advancing
12M Momentum+0.1%
6M Momentum+0.9%
Volatility+0.2%
Momentum & Technical
Momentum Acceleration-81.4%
Momentum ConsistencyWeak (0.10)
Relative Strength vs Sector-15.6%
Trend Strength (ADX Proxy)Weak (0.4)
Momentum Quality+0.048
Momentum BreadthBroad ✓
Macro Regime
Bull RegimeYes
High Vol RegimeNo
S&P 500 Return+25.0%
Yield Curve-0.1bp

Sector-Relative AnalysisIn-model features

Value Trap Signal
11%
Low risk
Sector RevGr Rank
P15
Revenue growth vs Healthcare peers
Sector PE Rank
P22
Valuation vs Healthcare peers
Sector FCF Rank
P62
Free cash flow vs Healthcare peers
Growth Deviation
-0.0σ
Z-score vs sector median
Stagnation Flag
NO
Not flagged

Analysis Signals

Scoring Factors
Fundamental score of 62 relative to sector peers62/100
Machine learning model ranks this stock at the 47th percentileP47
ML model weight reduced to 9% due to macro conditions: market in extended rally phase; yield curve inverted (recession indicator); late-cycle economic indicators detected9% ML weight
SHAP feature alignment: +1.2pt (features align with model priorities)—
Blend: 91% fund (62.3) + 9% ML (45.9) + SHAP(+1.2) = 62.0—
Factor quality: +0.4pt (multi-factor composite)—
Market cap adjustment: -4.0 points ($2.5B market cap)-4.0 pts
Divergence penalty: -0.7pt (fund 15pt higher)—
Risk Factors
Risk assessment: high. Annualized volatility 21.5%. Max drawdown 46% (-12.0 pts)High
Earnings quality grade D: weak earnings quality, multiple concerns. Score adjusted by -18 pointsGrade D
Quality concern: Non-operating loss: operating margin (-2.0%) exceeds net margin (-68.5%) by 67pp — possible write-down; High accrual ratio (111.0%) — earnings quality concernFlag

Sector Peer Comparison(Healthcare — Rank #248 of 344 stocks)

StockScoreP/ERev GrowthMarginMkt Cap
NEOG24.6N/A-3.2%-68.5%$2.5B
INCY89.915.821.2%25.0%$19.6B
GMAB86.113.122.8%36.4%$17.9B
CPRX83.713.723.5%37.6%$3.0B
EXEL78.315.17.0%33.7%$11.9B
ASND78.216.698.0%-31.7%$13.8B
VRTX78.232.18.9%32.9%$121.8B
NBIX75.126.521.4%16.7%$13.1B
RPRX75.025.15.1%32.4%$19.3B
HOLX74.831.11.7%13.8%$16.8B
AMGN74.226.010.0%21.0%$204.8B
ARGX73.735.178.6%38.0%$47.4B
REGN73.019.41.0%31.4%$80.2B
ALKS72.916.5-6.4%23.9%$5.0B
ISRG72.761.720.5%28.4%$180.9B
KRYS71.541.4473.0%30.7%$7.9B
Sector Average36.441.9161.5%-3292.7%—

Company Overviewvia FMP

Neogen Corporation, together with its subsidiaries, develops, manufactures, and markets various products for food and animal safety worldwide. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment offers diagnostic test kits and related products to detect dangerous and unintended substances in food and animal feed, including foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns; and AccuPoint Advanced rapid sanitation test to detect the presence of adenosine triphosphate, a chemical found in living cells. This segment offers its products primarily to food and feed producers and processors; grain producers and processors; producers of cookies, crackers, candy, ice cream, and other processed foods; meat and poultry processors, seafood processors, fruit and vegetable producers, and dairies; laboratories; and producers of pharmaceuticals, cosmetics, and veterinary vaccines. The Animal Safety segment provides veterinary instruments, pharmaceuticals, vaccines, topicals, parasiticides, diagnostic products, rodenticides, cleaners, disinfectants, insecticides, and genomics testing services for the animal safety market. This segment offers various products for researchers to detect biologically active substances. Its drug detection immunoassay test kits are used for the detection of abused and therapeutic drugs in farm and racing animals; detection of drug residues in meat and meat products; and human forensic toxicology drug screening applications. In addition, this segment's products are used to maintain sanitary conditions and limit the potential hazards of bacteria, fungi, and viruses. Neogen Corporation was incorporated in 1981 and is headquartered in Lansing, Michigan.

CEO
Mikhael Nassif
Employees
2,917
Beta
1.98
Industry
Medical - Diagnostics & Research
FMP-Identified Peers

Technical Picturecomputed from daily prices

RSI (14)
63.7
Neutral
Trend
Bullish
10-day vs 50-day MA
From 52W High
-2.4%
High: $11.43
From 52W Low
+188.2%
Low: $3.87
Moving Averages
10-Day
$11.10
Above
20-Day
$10.80
Above
50-Day
$9.30
Above
200-Day
$6.60
Above
60-Day Support
$5.81
60-Day Resistance
$11.43
Weinstein Stage Analysisbased on 200-day SMA framework
Stage 2 — AdvancingScore: 82/100

Stock is in an uptrend above the 200-day moving average. This is the stage where institutional accumulation typically occurs. The 50-day SMA provides support.

Favorable technical position; 50-day SMA acts as support
Price vs 200 SMA
+69%
200 SMA Slope (60d)
+4.78%
Rising
Volume Ratio
0.77x
10d avg vs 50d avg
Days in Stage
54
Confidence: 90%

Financial Statementslast 4 quarters via FMP

MetricQ2 2025Q1 2025Q4 2025Q3 2025
Revenue$225M$209M$225M$221M
Gross Profit$107M$72M$69M$87M
Operating Income$-5M$-16M$-8M$12M
Net Income$-16M$36M$-612M$-11M
EPS (Diluted)$-0.07$0.17$-2.82$-0.05
Gross Margin47.5%34.4%30.8%39.4%
Operating Margin-2.4%-7.6%-3.5%5.4%
Net Margin-7.1%17.4%-271.5%-5.0%

Why This Stock

Healthcare

Tradability FilterGrade A — 93/100Score impact: -24.6pt

Volume
100
3.9M avg/day
Dollar Vol
95
$43M/day
Float
100
216M shares
Mkt Cap
61
$2.5B
Range
100
193% spread
Composite Liquidity Score93/100
FDCBA

Multi-Year Range Analysis

Sideways: 6/100
YearLowHighRangeStatus
2021$38.62$48.8523.4%Narrow
2022$10.49$45.60125.2%Wide
2023$14.44$24.1050.2%Wide
2024$11.46$20.7257.6%Wide
2025$3.87$13.41110.4%Wide
3-Year Range
144.7%
Narrow Years
1 / 5
Sideways Penalty
None

Growth Projection Adjustment

0.7x dampening
slight revenue decline

Growth estimates have been dampened based on technical and fundamental signals. This is a post-hoc adjustment to prevent overly optimistic projections for stocks showing declining momentum or deteriorating fundamentals.

Free Float
99.2%
Outstanding Shares
218M
Bid-Ask Spread
193.0%
Institutional Tradable
Yes

Scores are generated by a multi-stage ML pipeline combining fundamental analysis, ensemble predictions, and structural risk signals. All data is for research purposes only and does not constitute financial advice. Past performance does not guarantee future results.